MedTrace Logo

Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)

NCT06659705 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2026-04-15

No results posted yet for this study

Summary

Assessment of the relevance of a new medical imaging test, FAPI PET, which could detect progression or relapse earlier than other tests currently available. Ultimately, it could enable early forms of pancreatic cancer to be detected and used for screening.

In addition to the usual examinations prescribed, FAPI PET scans will be repeated at several points in the treatment process.

All study patients must first have been included in the Homing cohort (NCT 04363983, APHP promotion). Clinical characteristics, judgement criteria and results of biological or imaging examinations carried out as part of this cohort will be shared.

Patient follow-up and participation in the study ends when conventional imaging (CT and MRI) shows disease progression, relapse or death.

Conditions

  • Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

DRUG

68Ga-FAPI-46 for PET / CT scan

Gallium 68-labeled fibroblast activation protein inhibitor (FAPI) used as radiotracer during PET imaging.

Sponsors & Collaborators

  • Institut Curie

    lead OTHER

Principal Investigators

  • Nicolas Deleval · Institut Curie

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-02
Primary Completion
2029-08-04
Completion
2030-08-08

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06659705 on ClinicalTrials.gov